Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Tango Therapeutics (NASDAQ: TNGX) announced inducement equity grants effective February 2, 2026 under its 2023 Inducement Plan. The Compensation Committee granted a non-qualified option for 367,500 shares at an exercise price of $11.94 and 60,000 RSUs to a new employee.

Options vest 25% on February 2, 2027 then monthly over 36 months; RSUs vest in three tranches of 20,000 on or about February 1, 2027, February 14, 2028 and February 12, 2029, subject to continued employment.

Key Figures

Stock option grant: 367,500 shares RSU grant: 60,000 units Exercise price: $11.94 per share +5 more

8 metrics

Stock option grant 367,500 shares Non-qualified stock option under 2023 Inducement Plan

RSU grant 60,000 units Restricted stock units to new employee

Exercise price $11.94 per share Equal to TNGX closing price on Feb 2, 2026

Option cliff vesting 25% on Feb 2, 2027 Initial vesting for stock option grant

Option monthly vesting 1/36 of remaining Monthly vesting after initial cliff, subject to employment

RSU tranche 1 20,000 shares Vesting on or about Feb 1, 2027

RSU tranche 2 20,000 shares Vesting on or about Feb 14, 2028

RSU tranche 3 20,000 shares Vesting on or about Feb 12, 2029

Market Reality Check

Price: $16.84 Vol: Volume 8,085,858 is 2.28x...

high vol

$16.84 Last Close

Volume Volume 8,085,858 is 2.28x the 20-day average of 3,543,968, indicating elevated trading activity before this filing. high

Technical Shares at $16.95 are trading above the 200-day MA of $8.04, near the $16.97 52-week high.

Peers on Argus

TNGX was up 36.28% with elevated volume, while key biotech peers showed mixed mo...

1 Up

TNGX was up 36.28% with elevated volume, while key biotech peers showed mixed moves (e.g., AVBP -7.79%, SANA -5.97%, IMTX -1.00%). Momentum scanner only flagged SANA briefly to the upside, suggesting TNGX’s strength was stock‑specific rather than sector‑wide.

Historical Context

5 past events · Latest: Mar 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Earnings and pipeline	Positive	+36.3%	Q4 and 2025 results plus cash runway and pivotal study plans.
Feb 18	Earnings date & conferences	Neutral	-3.0%	Announcement of Q4 2025 results date and investor conferences.
Feb 03	Investor conference	Neutral	+5.1%	CEO fireside chat at Guggenheim Emerging Outlook Biotech Summit.
Jan 08	CEO transition	Neutral	-6.2%	Founding CEO retirement and appointment of Malte Peters as CEO.
Jan 05	Board appointment	Neutral	-0.2%	Appointment of Sung Lee to Board of Directors for late-stage growth.

Pattern Detected

Recent TNGX news, especially earnings and pipeline updates, has often coincided with strong positive price reactions, while management changes have seen more muted or negative responses.

Recent Company History

Over the past two months, Tango Therapeutics has reported several notable developments. On Mar 5, 2026, Q4 and full‑year 2025 results highlighted $343.1 million in cash and plans for a pivotal pancreatic study, with the stock rising 36.28%. Earlier, the company pre‑announced its earnings date and conference participation, appointed Sung Lee to the board, and executed a CEO transition to Malte Peters. Today’s inducement equity grants fit into this broader phase of leadership change and organizational scaling.

Regulatory & Risk Context

Active S-3 Shelf · $15 million

Shelf Active

Active S-3 Shelf Registration 2025-11-21

$15 million registered capacity

An effective S-3 shelf filed on Nov 21, 2025 covers the resale of up to 1,732,101 previously issued shares from an October 2025 private placement at $8.66 per share. Tango will not receive proceeds from these secondary resales; the registration provides liquidity for the selling stockholder but does not itself add new capital or primary dilution.

Market Pulse Summary

This announcement details equity inducement awards of 367,500 options and 60,000 RSUs under the 2023...

Analysis

This announcement details equity inducement awards of 367,500 options and 60,000 RSUs under the 2023 Inducement Plan pursuant to Nasdaq Rule 5635(c)(4). It follows a period of notable corporate activity, including Q4 2025 earnings, a CEO transition, and new board appointments. Investors may monitor future grants, vesting schedules, and any additional resale activity under the existing registration for 1,732,101 shares when assessing potential dilution and ownership dynamics.

Key Terms

non-qualified stock option, restricted stock units (RSUs), Nasdaq Listing Rule 5635(c)(4), inducement plan, +1 more

5 terms

non-qualified stock option financial

"granted a non-qualified stock option to purchase 367,500 shares"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

restricted stock units (RSUs) financial

"and 60,000 restricted stock units (RSUs) to a new employee"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Nasdaq Listing Rule 5635(c)(4) regulatory

"pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"Tango Therapeutics' 2023 Inducement Plan is used exclusively for the grant"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

exercise price financial

"The options have an exercise price of $11.94 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $11.94 per share, which is equal to the closing price of Tango Therapeutics' common stock on February 2, 2026. Each option will vest as to 25% of the shares underlying such option on February 2, 2027 and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to such employee's continued employment on each vesting date. The RSU award will vest as to: (i) 20,000 shares on or about February 1, 2027, (ii) 20,000 shares on or about February 14, 2028, and (iii) 20,000 shares on or about February 12, 2029, subject to such employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors and Media:
Elizabeth Hickin
IR@tangotx.com
media@tangotx.com

FAQ

What equity grants did Tango Therapeutics (TNGX) announce on March 6, 2026?

They announced a non-qualified stock option for 367,500 shares and 60,000 RSUs to a new employee. According to Tango Therapeutics, the grants were made under the 2023 Inducement Plan effective February 2, 2026.

What is the exercise price and effective date of the TNGX option grant?

The option exercise price is $11.94 per share and is effective February 2, 2026. According to Tango Therapeutics, that price equals the closing share price on February 2, 2026.

How do the TNGX options vest for the new employee awarded 367,500 shares?

Options vest 25% on February 2, 2027, then 1/36th of the remaining shares monthly thereafter. According to Tango Therapeutics, vesting is contingent on the employee's continued employment on each vesting date.

What is the RSU vesting schedule for the 60,000 RSUs granted by TNGX?

The RSUs vest in three tranches of 20,000 shares on or about February 1, 2027; February 14, 2028; and February 12, 2029. According to Tango Therapeutics, each tranche vests subject to continued employment on the vesting date.

Under which plan were the inducement awards to the new TNGX employee made?

The awards were made under the 2023 Inducement Plan, approved in February 2023. According to Tango Therapeutics, this plan is used exclusively for inducement equity awards under Nasdaq Rule 5635(c)(4).